Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.
|
Authors | Samantha C Erosa, Paul R Haffey, Neel Mehta, Amitabh Gulati |
Journal | Current pain and headache reports
(Curr Pain Headache Rep)
Vol. 25
Issue 3
Pg. 18
(Feb 25 2021)
ISSN: 1534-3081 [Electronic] United States |
PMID | 33630185
(Publication Type: Journal Article, Systematic Review)
|
Chemical References |
- Analgesics, Opioid
- Levorphanol
- Buprenorphine
- Tapentadol
|
Topics |
- Analgesics, Opioid
(administration & dosage)
- Buprenorphine
(administration & dosage)
- Humans
- Levorphanol
(administration & dosage)
- Neuralgia
(diagnosis, drug therapy, epidemiology)
- Randomized Controlled Trials as Topic
(methods)
- Tapentadol
(administration & dosage)
- Treatment Outcome
|